Custom Search


Friday 01 June 2001

Ziprasidone: a new atypical antipsychotic.

By: Keck PE Jr, McElroy SL, Arnold LM.

Expert Opin Pharmacother 2001 Jun;2(6):1033-42

This paper reviews the clinical pharmacology, efficacy and safety of the new atypical antipsychotic, ziprasidone. All published citations regarding ziprasidone were retrieved and reviewed using a MEDLINE search (completed for citations to early 2001). In addition, abstracts from recent scientific meetings presenting data not yet published were reviewed. Like other new antipsychotic medications, ziprasidone fits the profile of an atypical agent, exerting efficacy in positive and negative symptoms of psychosis, as well as affective symptoms, with a low risk of neurological and neuroendocrinological side effects. Unlike newer agents, it does not appear to be associated with weight gain in most patients.

Use of this site is subject to the following terms of use